Chiome Bioscience Inc. (JP:4583)
:4583
Want to see JP:4583 full AI Analyst Report?
Top Page
Chiome Bioscience Inc.
(4583)
Select Model
Select Model
Rating:40Underperform
Price Target:
¥72.00
▼(-32.08% Downside)
Action:Downgraded
Date:06/03/26
The score is driven primarily by weak financial performance (persistent losses and ongoing cash burn) and bearish technicals (price below major moving averages with negative momentum). Valuation provides only limited support because the company is loss-making and no dividend yield is available.
Positive Factors
Proprietary ADC/antibody platform
Chiome's proprietary antibody and ADC discovery platform creates a durable competitive asset: platforms can generate multiple candidates, attract partnerships and non-dilutive funding, and create long-term licensing or royalty revenue streams if clinical success occurs.
Negative Factors
Persistent negative cash flow
Operating and free cash flows have been materially negative and track accounting losses, creating a sustained cash burn. Over a multi-month horizon this increases funding risk, may force dilutive financings or accelerated partnerships, and constrains independent program funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary ADC/antibody platform
Chiome's proprietary antibody and ADC discovery platform creates a durable competitive asset: platforms can generate multiple candidates, attract partnerships and non-dilutive funding, and create long-term licensing or royalty revenue streams if clinical success occurs.
Read all positive factors
Chiome Bioscience Inc. (4583) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥5.28B
Dividend YieldN/A
Average Volume (3M)521.30K
Price to Earnings (P/E)―
Beta (1Y)0.74
Revenue Growth-23.82%
EPS Growth14.80%
CountryJP
Employees47
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-15.69
Shares Outstanding76,543,100
10 Day Avg. Volume796,530
30 Day Avg. Volume521,303
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)6.47
Price to Sales (P/S)12.25
P/FCF Ratio-7.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Chiome Bioscience Inc. Business Overview & Revenue Model
Company Description
Chiome Bioscience Inc. is a global company dedicated to the research and development of cutting-edge technology platforms for drug discovery. Its operations are structured into two primary divisions: the Drug Discovery Business and the Drug Discov...
How the Company Makes Money
null...
Chiome Bioscience Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 768.88M | 593.29M | 780.81M | 682.46M | 630.82M | 712.93M |
| Gross Profit | 436.96M | 355.58M | 432.02M | 397.72M | 347.78M | 420.59M |
| EBITDA | -989.98M | -972.64M | -1.01B | -1.21B | -1.24B | -1.46B |
| Net Income | -997.11M | -982.78M | -1.02B | -1.22B | -1.24B | -1.48B |
Balance Sheet | ||||||
| Total Assets | 1.96B | 1.73B | 2.47B | 1.75B | 2.22B | 2.34B |
| Cash, Cash Equivalents and Short-Term Investments | 1.47B | 1.21B | 2.06B | 1.33B | 1.73B | 1.79B |
| Total Debt | 260.50M | 261.70M | 281.50M | 291.00M | 184.00M | 183.00M |
| Total Liabilities | 443.39M | 605.44M | 548.55M | 593.73M | 424.72M | 446.39M |
| Stockholders Equity | 1.52B | 1.12B | 1.92B | 1.16B | 1.79B | 1.89B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -976.07M | -1.00B | 0.00 | -1.19B | 0.00 |
| Operating Cash Flow | 0.00 | -935.99M | -1.00B | -1.07B | -1.19B | -1.13B |
| Investing Cash Flow | 0.00 | -55.46M | 0.00 | 173.00K | 0.00 | -35.38M |
| Financing Cash Flow | 0.00 | 133.20M | 1.74B | 667.30M | 1.13B | 271.35M |
Chiome Bioscience Inc. Technical Analysis
Negative
106.00
Price Trends
92.72
Negative
101.98
Negative
113.92
Negative
Market Momentum
-7.30
Positive
21.85
Positive
23.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4583, the sentiment is Negative. The current price of 106 is above the 20-day moving average (MA) of 80.50, above the 50-day MA of 92.72, and below the 200-day MA of 113.92, indicating a bearish trend. The MACD of -7.30 indicates Positive momentum. The RSI at 21.85 is Positive, neither overbought nor oversold. The STOCH value of 23.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4583.
Chiome Bioscience Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ¥8.54B | 25.96 | ― | ― | 3.66% | 32.11% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥11.23B | 222.65 | ― | ― | 11.45% | ― | |
47 Neutral | ¥90.89B | -8.92 | -19.31% | ― | 10.88% | -327.56% | |
47 Neutral | ¥72.21B | -43.49 | ― | ― | 0.80% | 32.87% | |
41 Neutral | ¥121.06B | -33.74 | -10.16% | ― | -59.19% | -124.16% | |
40 Underperform | ¥5.28B | -5.11 | ― | ― | -23.82% | 14.80% |
* Healthcare Sector Average
JP:4583
Chiome Bioscience Inc.
69.00
-83.00
-54.61%
JP:4587
Peptidream
932.50
-728.00
-43.84%
JP:4565
Sosei Group
983.00
63.00
6.85%
JP:4570
Immuno-Biological Laboratories Co., Ltd.
917.00
404.20
78.82%
JP:4579
RaQualia Pharma Inc.
459.00
-158.00
-25.61%
JP:4588
Oncolys BioPharma, Inc.
2,467.00
1,853.00
301.79%
Chiome Bioscience Inc. Corporate Events
Chiome Bioscience Outlines Q1 FY2026 Results and Pipeline Focus
May 14, 2026
Chiome Bioscience Inc. reported supplementary information for its financial results for the first quarter of fiscal year ending December 2026. The materials outline both financial performance and operational highlights, indicating continued focus ...
Chiome Bioscience Narrows Quarterly Loss as Equity Ratio Improves, Keeps Cautious Outlook
May 14, 2026
Chiome Bioscience reported non-consolidated net sales of ¥147 million for the first quarter ended March 31, 2026, a 6.1% year-on-year increase, while trimming its net loss to ¥233 million as operating and ordinary losses narrowed. Total ...
Chiome Bioscience Corrects FY2025 Results as Losses and Cash Burn Persist
Mar 27, 2026
Chiome Bioscience has issued an updated version of its non-consolidated financial results for the fiscal year ended December 31, 2025, correcting specific items related to share count, cash flow statements, segment information, and per-share data....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.